Cargando…

334. Weight Change Associated with Antiretroviral Therapy Switch to Integrase Strand Transfer Inhibitor-Based Regimens

BACKGROUND: An association between switching antiretroviral therapy (ART) to integrase strand transfer inhibitor (INSTI)-based ART and weight gain has been previously reported. However, insufficient data exists on risk factors associated with such weight gain. METHODS: We reviewed charts of 119 vira...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saber, Saghar, Bernstein, Andrew B, Sparks, Andrew D, Siegel, Marc O
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810182/ http://dx.doi.org/10.1093/ofid/ofz360.407

Ejemplares similares

Initiation of antiretroviral therapy with integrase strand-transfer inhibitor-based regimens and reduction of the risk of horizontal transmission of HIV-1
por: Berenguer, Juan, et al.
Publicado: (2019)

Integrase Strand Transfer Inhibitors in HIV Therapy
por: Mesplède, Thibault, et al.
Publicado: (2013)

1566. Determinants associated with weight gain among persons with HIV who switch to integrase strand transfer inhibitors (INSTI)
por: Cutshaw, Melissa Klein, et al.
Publicado: (2023)

Weight Gain and Lipid Profile Changes in Koreans with Human Immunodeficiency Virus undergoing Integrase Strand Transfer Inhibitor-Based Regimens
por: Kim, Jin, et al.
Publicado: (2022)

Weight Gain After Switch from Efavirenz-Based to Integrase Inhibitor-Based Regimens
por: Norwood, Jamison, et al.
Publicado: (2017)

No evidence of rapid reversibility of tenofovir alafenamide and/or integrase strand transfer inhibitor-associated weight gain
por: Verburgh, Myrthe L., et al.
Publicado: (2023)

Pharmacokinetic drug interactions of integrase strand transfer inhibitors
por: Lu, Chi-Hua, et al.
Publicado: (2021)

HIV-1 Integrase Strand Transfer Inhibitors and Neurodevelopment
por: Foster, Emma G., et al.
Publicado: (2022)

Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor–Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance
por: Demarest, James, et al.
Publicado: (2018)

333. Weight Gain Among HIV-Infected Patients in Southern India on Treatment with Integrase Strand Transfer Inhibitor-based Antiretroviral Therapy
por: Khan, Rifa, et al.
Publicado: (2019)

Primary resistance against integrase strand transfer inhibitors in integrase strand transfer inhibitor-naive patients failing first- and second-line ART in Tanzania
por: Henerico, Shimba, et al.
Publicado: (2022)

Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens
por: Gil, Horacio, et al.
Publicado: (2022)

Real-world weight changes in people with HIV-1 at risk of weight gain (female, Black or Hispanic) switching from integrase strand transfer inhibitors
por: Donga, Prina, et al.
Publicado: (2022)

Multiple choices for HIV therapy with integrase strand transfer inhibitors
por: Raffi, Francois, et al.
Publicado: (2012)

Structure-Guided Optimization of HIV Integrase Strand Transfer Inhibitors
por: Zhao, Xue Zhi, et al.
Publicado: (2017)

HIV drug resistance against strand transfer integrase inhibitors
por: Anstett, Kaitlin, et al.
Publicado: (2017)

Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs
por: Smith, Steven J., et al.
Publicado: (2021)

Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance
por: Richetta, Clémence, et al.
Publicado: (2022)

Pretreatment integrase strand transfer inhibitor resistance in Tianjin, China
por: Xia, Huan, et al.
Publicado: (2023)

HIV-1 Integrase Strand Transfer Inhibitors with Reduced Susceptibility to Drug Resistant Mutant Integrases
por: Zhao, Xue Zhi, et al.
Publicado: (2016)

One in 10 Virally Suppressed Persons With HIV in The Netherlands Experiences ≥10% Weight Gain After Switching to Tenofovir Alafenamide and/or Integrase Strand Transfer Inhibitor
por: Verburgh, Myrthe L, et al.
Publicado: (2022)

Weight Gain in Incarcerated Individuals Living With HIV After Switching to Integrase Strand Inhibitor-Based Therapy
por: Goldberg, Rachel N., et al.
Publicado: (2021)

Incidence of cardiometabolic outcomes among people living with HIV‐1 initiated on integrase strand transfer inhibitor versus non‐integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States
por: Rebeiro, Peter F., et al.
Publicado: (2023)

Surveillance of HIV-1 transmitted integrase strand transfer inhibitor resistance in the UK
por: Mbisa, Jean L, et al.
Publicado: (2020)

Integrase Strand Transfer Inhibitor Resistance Mutations in Antiretroviral Treatment-naïve Patients in Korea: a Prospective, Observational Study
por: Kim, Yeonjae, et al.
Publicado: (2018)

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence
por: Mesplède, Thibault, et al.
Publicado: (2015)

Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in Taiwan
por: Chang, Sui-Yuan, et al.
Publicado: (2016)

HIV-1 integrase strand-transfer inhibitor resistance in southern Taiwan
por: Tsai, Hung-Chin, et al.
Publicado: (2018)

Inhibition of matrix metalloproteinases by HIV-1 integrase strand transfer inhibitors
por: Foster, Emma G., et al.
Publicado: (2023)

1568 Use of the Integrase Strand Transfer Inhibitor-Based Antiretroviral Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in a Predominantly African-American HIV Infected Population
por: Bryant, Paul, et al.
Publicado: (2014)

Virological and Immunological Outcomes of an Intensified Four-Drug versus a Standard Three-Drug Antiretroviral Regimen, Both Integrase Strand Transfer Inhibitor-Based, in Primary HIV Infection
por: Mondi, Annalisa, et al.
Publicado: (2022)

Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors
por: Malet, Isabelle, et al.
Publicado: (2017)

Integrase Strand Transfer Inhibitors and Weight Gain in Children and Youth With Perinatal Human Immunodeficiency Virus in the DC Cohort
por: Koay, Wei Li A, et al.
Publicado: (2021)

High predictive efficacy of integrase strand transfer inhibitors in perinatally HIV-1-infected African children in therapeutic failure of first- and second-line antiretroviral drug regimens recommended by the WHO
por: Mboumba Bouassa, Ralph-Sydney, et al.
Publicado: (2019)

Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV
por: Dow, Dorothy E., et al.
Publicado: (2014)

Resistance to HIV integrase strand transfer inhibitors in Argentina: first interim survey
por: Cecchini, Diego M., et al.
Publicado: (2019)

Real-World Assessment of Weight Change in People with HIV-1 After Initiating Integrase Strand Transfer Inhibitors or Protease Inhibitors
por: Chen, Yen-Wen, et al.
Publicado: (2020)

Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting
por: Greenberg, Lauren, et al.
Publicado: (2022)

Temporary increase in circulating replication-competent latent HIV-infected resting CD4+ T cells after switch to an integrase inhibitor based antiretroviral regimen
por: Ferreira, Roux-Cil, et al.
Publicado: (2023)

Gut Bacterial Communities in HIV-Infected Individuals with Metabolic Syndrome: Effects of the Therapy with Integrase Strand Transfer Inhibitor-Based and Protease Inhibitor-Based Regimens
por: Baltazar-Díaz, Tonatiuh Abimael, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_420lfam66nksr2ti9h8hbebqnb